Guangzhou Daily (All media reporter Zhou Jieying correspondent Cha Guanlin) Breast enlargement really does not need intervention? “Actually, it still depends on the situation. Even if it is benign, if it affects the quality of life, it is certainly necessary to make appropriate interventions.” Professor Chen Qianjun, president of the Breast Disease Branch of the Chinese Academy of Traditional Chinese Medicine and director of the Breast Department of the provincial Chinese medicine, was interviewed at the recent Seventh Yangcheng Forum on Breast Disease and the Eighth Annual Academic Conference of the Breast Disease Professional Committee of the Guangdong Association of Traditional Chinese Medicine. The annual meeting also released the “Guidelines for the Clinical Application of Proprietary Chinese Medicines in the Treatment of Mastopathy (2021 Edition)” (hereinafter referred to as the “Guidelines”), which provides reference and guidance for the rational application of proprietary Chinese medicines in the treatment of mastopathy.
Mammary gland hyperplasia is a problem that most women will face to varying degrees throughout their lives. How to treat it? In many people’s perception, it is a very common benign disease that generally does not need to be treated, but in reality, there are still many people who will feel discomfort. “Should I treat breast enlargement? It may not be fatal in many cases and will not affect the length of life, but it will affect the ‘width’ of life, that is, when the symptoms are severe, it will affect the life work , so that the quality of life of female friends is affected, in this case, of course, to cure.” Chen Qianjun said that appropriate intervention management is necessary.
The current consensus of the modern medical system for the treatment of mastocytosis is that for those with mild to moderate pain to psychological guidance and changes in lifestyle habits, histopathological examination if necessary. For patients with severe pain, relevant medications can be given. Chinese patent medicines are an important clinical choice, but there are many varieties of Chinese patent medicines, and their identification, usage and clinical application indications have not been standardized, and there is no relevant reference basis. Chen Qianjun said that the release of the Guidelines is to solve the current problem of how to apply relevant proprietary Chinese medicines in the modern medical system, to provide clinicians with general principles for the selection of proprietary Chinese medicines for the treatment of breast hyperplasia, and to provide reference for patients to understand the relevant information, which is of great significance to optimize the treatment plan of proprietary Chinese medicines for breast hyperplasia and the rational use of proprietary Chinese medicines.
